Interleukin-1 drives cerebrovascular inflammation via MAP kinase-independent pathways

Curr Neurovasc Res. 2010 Nov;7(4):330-40. doi: 10.2174/156720210793180800.

Abstract

Cerebrovascular inflammation is triggered by diverse central nervous system (CNS) insults and contributes to disease pathogenesis. The pro-inflammatory cytokine interleukin (IL)-1 is central to this cerebrovascular inflammatory response and understanding the underlying signalling mechanisms of IL-1 actions in brain endothelium may provide therapeutic targets for disease intervention. For the first time, we compare the contributions of p38, JNK and ERK mitogen-activated protein (MAP) kinase and NF-kB pathways to IL-1-induced brain endothelial activation. In cultures of primary mouse brain endothelium and the rat brain endothelial GPNT cell line, interleukin-1β (IL-1β induced a rapid (within 5 minutes) and transient activation of p38 and JNK (but not ERK) MAP kinases. IL-1β also induced nuclear recruitment of nuclear factor (NF)-kB p65. IL-1β-induced brain endothelial expression of intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 was insensitive to MAP kinase inhibitors. IL-1β-induced brain endothelial expression of ICAM-1 and VCAM-1 was inhibited (80-88 %) by the proteasome inhibitor MG132 or the antioxidant caffeic acid phenethyl ester (CAPE), effects suggested to be NF-kB-dependent. IL-1β-induced brain endothelial CXCL1 expression was partially inhibited by JNK MAP kinase or MG132 (62 or 56 %, respectively). However, CXCL1 secretion from brain endothelium was reduced (65 %) only by MG132, and not MAP kinase inhibitors. Similarly, IL-1β-induced neutrophil transendothelial migration was reduced (77-89 %) by MG132, but not MAP kinase inhibitors. In summary, we show that several key components of IL-1β-induced brain endothelial activation (CAM, CXCL1 expression or release and neutrophil transmigration) are largely independent of MAP kinase activity but are reduced by proteasome inhibition, possibly reflecting a requirement for NF-kB activity. Similar mechanisms may contribute to cerebrovascular inflammation in response to CNS injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Brain / cytology
  • Cell Movement / drug effects
  • Cells, Cultured
  • Cycloheximide / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Endothelial Cells / drug effects*
  • Endothelial Cells / enzymology
  • Enzyme Inhibitors / pharmacology
  • Enzyme-Linked Immunosorbent Assay / methods
  • Gene Expression Regulation, Enzymologic / drug effects*
  • Interleukin 1 Receptor Antagonist Protein / pharmacology
  • Interleukin-1 / pharmacology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitogen-Activated Protein Kinase Kinases / metabolism*
  • NF-kappa B / metabolism
  • Platelet Endothelial Cell Adhesion Molecule-1 / metabolism
  • Protein Synthesis Inhibitors / pharmacology
  • Rats
  • Signal Transduction / drug effects*

Substances

  • Enzyme Inhibitors
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • NF-kappa B
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Protein Synthesis Inhibitors
  • Cycloheximide
  • Mitogen-Activated Protein Kinase Kinases